Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.32 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6047160 | 0.88 | MEN1 (0.39) | CTSKMEN1KMT2ACASRSLC6A1 | |
| SCHEMBL4285689 | 0.82 | CA1 (0.39) | CTSKCA1CA2MEN1KMT2A | |
| SCHEMBL4292637 | 0.82 | CA1 (0.39) | CTSKCA1CA2MEN1KMT2A | |
| SCHEMBL28516842 | 0.81 | KIF11 (0.37) | MEN1KMT2AAHRSLC6A1SLC6A11 | |
| SCHEMBL8717149 | 0.79 | CA1 (0.53) | CA1CA2MEN1KMT2AALDH1A1 | |
| SCHEMBL10769223 | 0.78 | KMT2A (0.44) | CTSKMEN1KMT2AALDH1A1 | |
| SCHEMBL5384418 | 0.77 | MEN1 (0.44) | CTSKMEN1KMT2A | |
| SCHEMBL19522241 | 0.75 | SLC6A1 (0.44) | MEN1KMT2ASLC6A1SLC6A11 | |
| SCHEMBL4284462 | 0.75 | CA1 (0.51) | CA1CA2MEN1KMT2AALDH1A1 | |
| SCHEMBL20742533 | 0.73 | CTSK (0.39) | CTSKCA1CA2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592807-A4 | ASSAY FOR DETECTING METHYLATION CHANGES IN NUCLEIC ACIDS USING AN INTERCALATING NUCLEIC ACID | HUMAN GENETIC SIGNATURES PTY (AU) | 2007-09-05 | — | — | EP | claimed |
| US-20070042365-A1 | Assay for detecting methylation changes in nucleic acids using an intercalating nucleic acid | HUMAN GENETIC SIGNATURES PTY. LTD. (AU) | 2007-02-22 | — | — | US | claimed |
| EP-1592807-A1 | ASSAY FOR DETECTING METHYLATION CHANGES IN NUCLEIC ACIDS USING AN INTERCALATING NUCLEIC ACID | Human Genetic Signatures PTY Ltd. (AU) | 2005-11-09 | — | — | EP | claimed |
| WO-2004065625-A1 | ASSAY FOR DETECTING METHYLATION CHANGES IN NUCLEIC ACIDS USING AN INTERCALATING NUCLEIC ACID | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2004-08-05 | — | — | WO | claimed |
| US-8598088-B2 | Methods for simplifying microbial nucleic acids by chemical modification of cytosines | HUMAN GENETIC SIGNATURES PTY. LTD. (AU) | 2013-12-03 | — | — | US | disclosed |
| EP-1888748-B1 | STABLE AND SELECTIVE FORMATION OF HOOGSTEEN-TYPE TRIPLEXES AND DUPLEXES USING TWISTED INTERCALATING NUCLEIC ACIDS (TINA) AND PROCESS FOR THE PREPARATION OF TINA | TINA HOLDING APS (DK) | 2013-08-28 | — | — | EP | disclosed |
| US-8343738-B2 | Assay for screening for potential cervical cancer | HUMAN GENETIC SIGNATURES PTY. LTD. (AU) | 2013-01-01 | — | — | US | disclosed |
| EP-1943353-B1 | ASSAY FOR A HEALTH STATE | HUMAN GENETIC SIGNATURES PTY (AU) | 2011-11-02 | — | — | EP | disclosed |
| US-20110136098-A1 | METHODS FOR SIMPLIFYING MICROBIAL NUCLEIC ACIDS BY CHEMICAL MODIFICATION OF CYTOSINES | HUMAN GENETIC SIGNATURES PTY. LTD. (AU) | 2011-06-09 | — | — | US | disclosed |
| US-7833942-B2 | Methods for simplifying microbial nucleic acids by chemical modification of cytosines | HUMAN GENETIC SIGNATURES PTY. LTD. (AU) | 2010-11-16 | — | — | US | disclosed |
| US-7799525-B2 | Methods for genome amplification | HUMAN GENETIC SIGNATURES PTY LTD. (AU) | 2010-09-21 | — | — | US | disclosed |
| EP-1641936-B1 | METHODS FOR GENOME AMPLIFICATION | HUMAN GENETIC SIGNATURES PTY (AU) | 2010-08-04 | — | — | EP | disclosed |
| WO-2006066353-A9 | DETECTION OF HUMAN PAPILLOMA VIRUS | HUMAN GENETIC SIGNATURES PTY (AU) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006066353-A1 | DETECTION OF HUMAN PAPILLOMA VIRUS | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006058393-A1 | METHODS FOR SIMPLIFYING MICROBIAL NUCLEIC ACIDS BY CHEMICAL MODIFICATION OF CYTOSINES | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2006-06-08 | — | — | WO | disclosed |
| EP-1641936-A1 | METHODS FOR GENOME AMPLIFICATION | Human Genetic Signatures PTY Ltd. (AU) | 2006-04-05 | — | — | EP | disclosed |
| EP-1592807-A1 | ASSAY FOR DETECTING METHYLATION CHANGES IN NUCLEIC ACIDS USING AN INTERCALATING NUCLEIC ACID | Human Genetic Signatures PTY Ltd. (AU) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004111266-A1 | METHODS FOR GENOME AMPLIFICATION | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004101816-A1 | DECOYS FOR NUCLEIC ACID-BINDING PROTEINS | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004065625-A1 | ASSAY FOR DETECTING METHYLATION CHANGES IN NUCLEIC ACIDS USING AN INTERCALATING NUCLEIC ACID | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042365-A1 | Assay for detecting methylation changes in nucleic acids using an intercalating nucleic acid | DNMT1, DNMT3A, NSUN2 | CTSK 4502/4885CA1 1505/4885CA2 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.